First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...

Researchers will use Cellply's VivaCyte platform to conduct single-cell analyses of NK cells and evaluate their ability to treat the bone marrow cancer.

Swedish cancer patients treated with CAR T-cell therapy show better survival rates and fewer side effects than seen in ...

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor ...

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment.

Nkure Therapeutics and Crispr Therapeutics partner to develop off-the-shelf CAR T therapy for oncology in India.

High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced ...

Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current ...